Medical Condition News

RSS

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

4 Jun 2011

Five years after cancer treatment, many survivors still suffer symptoms

When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study -- one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.

4 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Nano-formulated indomethacin at lower dose effective in treating pain

A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society.

4 Jun 2011

Maryland researchers deny link between cell phone radiation and brain cancer

University of Maryland researchers in the A. James Clark School of Engineering have expressed concerns regarding the validity of recent findings announced in the Journal of the American Medical Association and a World Health Organization panel suggesting that radiation from cell phones may be carcinogenic.

4 Jun 2011

Enzyme Research journal publishes new peer-reviewed article involving Protandim

LifeVantage Corporation, the maker of Protandim, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim was published in the scientific journal Enzyme Research.

4 Jun 2011

Johns Hopkins researchers solve long-standing mystery of Warburg effect

It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar.

4 Jun 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

4 Jun 2011

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

A new therapy for type 1 diabetes? A promising treatment for deadly viruses? Does a common treatment for children with severe infection actually cause more harm than good? These are important questions being investigated by pediatric researchers at Mattel Children's Hospital UCLA.

4 Jun 2011

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group investigators.

4 Jun 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia.

4 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

New discoveries about role of blood vessels in early lung development

A research team at The Saban Research Institute of Children's Hospital Los Angeles has made critical new discoveries about the role of blood vessels in guiding early lung development, especially in the essential, highly reproducible branching pattern of lung airways.

4 Jun 2011

Insight into understanding of normal muscle growth

Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell's territory, eventually forcing the cells to combine.

4 Jun 2011

Frequent spousal communication linked to lower PTSD symptoms in happily married soldiers

A new study from the Journal of Traumatic Stress finds that for active-duty male soldiers in the U.S. Army who are happily married, communicating frequently with one's spouse through letters and emails during deployment may protect against the development of posttraumatic stress disorder (PTSD) symptoms after returning home.

4 Jun 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

U of Alberta researchers win Canadian Society of Chemistry award

A one-of-a-kind Canadian research group, based in the Faculty of Medicine & Dentistry at the University of Alberta, has now won every award handed out by the Canadian Society of Chemistry for analytical and environmental chemistry.

4 Jun 2011

Scientists identify chromosomal mutation responsible for excessive hair growth

Researchers in the Keck School of Medicine of the University of Southern California (USC), together with scientists in Beijing, China, have discovered a chromosomal mutation responsible for a very rare condition in which people grow excess hair all over their bodies.

4 Jun 2011

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

YM BioSciences Inc., today reported updated interim safety and efficacy results from the Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.

4 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Medical Condition News

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Five years after cancer treatment, many survivors still suffer symptoms

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Nano-formulated indomethacin at lower dose effective in treating pain

Maryland researchers deny link between cell phone radiation and brain cancer

Enzyme Research journal publishes new peer-reviewed article involving Protandim

Johns Hopkins researchers solve long-standing mystery of Warburg effect

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

New discoveries about role of blood vessels in early lung development

Insight into understanding of normal muscle growth

Frequent spousal communication linked to lower PTSD symptoms in happily married soldiers

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

U of Alberta researchers win Canadian Society of Chemistry award

Scientists identify chromosomal mutation responsible for excessive hair growth

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News